New Delhi: The Drug Controller General of India (DCGI) has approved 25 new drugs this year which includes three coronavirus drugs, an official said on Saturday.
DCGI official explained that Remdesivir injection five ml and remdesivir Lyophilised Powder for Injection 100 mg has been approved for the treatment of suspected or confirmed coronavirus cases.
Similarly, Favipiravir bulk tablets 200 mg as well as Favipiravir film-coated tablets 400 mg has been approved for the treatment of patients with mild to moderate coronavirus symptoms.
Drugs like Sucroferric oxyhydroxide bulk and Sucroferric oxyhydroxide chewable tablet 500 mg was also approved for the control of serum phosphorous levels in patients with chronic kidney disease on dialysis.
Also read: Bhopal woman given talaq over phone, MP CM promises justice
The subject expert committee of the DCGI, meanwhile, has asked global pharma giant Novartis to submit clarification on inclusion and exclusion criteria of the cytokine storm. This followed after representatives from Novartis presented their proposal for conducting the phase III global clinical trial of Ruxolitinib 5 mg for COVID-19 patients.
Study on this drug indicates that the treatment of COVID-19 or severe acute respiratory syndrome with ruxolitinib 5mg consumed every 12 hours during 14 days would stop the disproportionate inflammatory response, in the patients who show a progression and worsening of the severe acute respiratory syndrome.
Meanwhile, officials in the Health Ministry said that India conducted 10,23,836 tests on Friday, these tests have been conducted through 1511 laboratories across the nation.
